Trial Profile
A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally Daily to Subjects With Solid Tumors.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 26 Jun 2023
Price :
$35
*
At a glance
- Drugs Foretinib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; GSK
- 26 Aug 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 26 Aug 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 26 Aug 2009 Actual end date (May 2009) added as reported by ClinicalTrials.gov.